Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin-Reference-Cited by-同舟云学术

Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin

Published:2016-07 Issue:7 Volume:32 Page:660-667
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Petersen Tess¹,Lee Yu-Jin¹,Osinusi Anu¹²³,Amorosa Valerianna K.⁴⁵,Wang Crystal¹,Kang Minhee⁶,Matining Roy⁶,Zhang Xiao¹,Dou Diana¹,Umbleja Triin⁶,Kottilil Shyam¹²,Peters Marion G.⁷

Affiliation:

1. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

2. Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.

3. Gilead Sciences Inc., Foster City, California.

4. Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania.

5. University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

6. Harvard School of Public Health, Boston, Massachusetts.

7. University of California at San Francisco, San Francisco, California.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.2015.0236

Reference21 articles.

1. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

2. Short Communication: Interferon/Ribavirin Treatment for HCV Is Associated with the Development of Hypophosphatemia in HIV/Hepatitis C Virus-Coinfected Patients

3. Changes in Mortality Related to Human Immunodeficiency Virus Infection: Comparative Analysis of Inpatient Deaths in 1995 and in 1999–2000

4. Trends in Diseases Reported on U.S. Death Certificates That Mentioned HIV Infection, 1987–1999

5. Progression of Chronic Hepatitis C to Liver Fibrosis and Cirrhosis in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein;Frontiers in Microbiology;2023-08-29

2. A determination of pan-pathogen antimicrobials?;Medicine in Drug Discovery;2022-06

3. Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?;ACS Infectious Diseases;2020-12-22

4. The Role of the Liver-Specific microRNA, miRNA-122 in the HCV Replication Cycle;International Journal of Molecular Sciences;2020-08-07

5. The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus;iScience;2019-09